Clinical trials
Legg-Calve-Perthes Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 4 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 2 |
| Zimmer Biomet | 2 |
| Ankara City Hospital Bilkent | 1 |
| Assaf-Harofeh Medical Center | 1 |
| Ataturk University | 1 |
| Banc de Sang i Teixits | 1 |
| Bezirkskrankenhaus St. Johann in Tirol | 1 |
| Bone Therapeutics S.A | 1 |
| British Columbia Children's Hospital | 1 |
| Cytex Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Legg-Calve-Perthes Disease | 25 |
| Osteonecrosis | 12 |
| Femur Head Necrosis | 5 |
| Osteoarthritis | 4 |
| Bone Diseases | 3 |
| Musculoskeletal Diseases | 3 |
| Osteoarthritis, Hip | 3 |
| Arthritis, Rheumatoid | 2 |
| Anemia, Sickle Cell | 1 |
| Collagen Diseases | 1 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.